The Aurora Ménage à Trois: Three Shifts in Seven Days
Curaleaf Holdings’ battle to acquire Aurora Cannabis has shifted in favour of the Canadian producer on multiple fronts over the last week.
Curaleaf Holdings’ battle to acquire Aurora Cannabis has shifted in favour of the Canadian producer on multiple fronts over the last week.
The M&A scramble for Europe has continued at a fearsome pace over the last few weeks.
Last week’s rescheduling announcement has placed a spotlight firmly on the medical cannabis arms of North America’s largest operators.
Cannabis stocks have once again been sent flying in the wake of the latest hint of progress on cannabis rescheduling from Trump’s White House.
Last month, the German cannabis market saw its most significant consolidation deal to date, as Canadian heavyweight Organigram announced plans to acquire Sanity Group in a deal worth up to €250m.
A national class action has been brought against Aurora Cannabis in Canada, alleging that the company ‘negligently’ failed to warn consumers about the risk of developing Cannabinoid Hyperemesis Syndrome (CHS).
With Aurora Cannabis and High Tide consolidating their presence across Europe, with a focus on Germany, how will this lucrative supply chain be impacted by shifting geopolitical dynamics?
As Canada works out how to deal with calls from its southern neighbour to become the 51st US state, it is expanding its own invasion on a very different front.
US cannabis stocks have rebounded this week as the industry got the opportunity to air their frustrations over a lack of access to banking to the Senate.